Core Viewpoint - Rongchang Biopharmaceuticals experienced a significant increase in stock price and trading volume, indicating strong market interest and investor confidence in the company [1][2]. Group 1: Financial Performance - For the year 2025, Rongchang Biopharmaceuticals achieved a revenue of 3.251 billion yuan, representing a year-on-year growth of 89.36% [2]. - The net profit attributable to shareholders for the same period was 710 million yuan, reflecting a substantial increase of 148.33% compared to the previous year [2]. Group 2: Stock and Financing Activity - On March 30, Rongchang Biopharmaceuticals saw a stock price increase of 5.52%, with a trading volume of 1.77 billion yuan [1]. - The company had a net financing purchase of 60.09 million yuan on the same day, with a total financing balance of 768 million yuan, which is 3.57% of its market capitalization [1]. - The financing balance is above the 70th percentile of the past year, indicating a high level of investor engagement [1]. Group 3: Shareholder Composition - As of December 31, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 9.0675 million shares, an increase of 225,700 shares from the previous period [3]. - New institutional investors include Yongying Medical Innovation Mixed Fund, which holds 4.6739 million shares [3]. - Other notable changes include a decrease in holdings by Wan Jia You Xuan and an increase by Hui Tian Fu Innovation Medical Mixed Fund [3].

Important Events - Moore Threads signed a contract worth 660 million yuan for the Moore Threads Quasar Intelligent Computing Cluster [1] - Jingwang Electronics has begun shipping 1.6T optical module PCBs [1] - Oni Electronics signed a strategic cooperation agreement for AI workstations with Muxi Co., Ltd [1] - Jerry Holdings signed a sales contract for gas turbine generator sets worth 2.359 billion yuan [1] - China Merchants Energy ordered 10 VLCC oil tankers at a total price of approximately 8.566 billion yuan [1] - China Shipbuilding (core stock) signed a contract for the construction of 10 very large crude carriers with a domestic well-known shipowner, with a value between 8 billion to 9 billion yuan [1] Investment - Dongpeng Beverage plans to use no more than 15 billion yuan of idle self-owned funds for cash management by 2026 [1] - TCL Technology intends to acquire a 45% stake in Guangzhou Huaxing Semiconductor (core stock) for a transaction price of 9.325 billion yuan [1] Buybacks & Increases - China Eastern Airlines plans to repurchase shares worth 500 million to 1 billion yuan, which will all be canceled to reduce registered capital, with a repurchase price not exceeding 5 yuan per share [1] Performance - Agricultural Bank (core stock) expects double-digit growth in revenue and profit by 2025, with average daily RMB deposits growing at the fastest rate in the industry [1] - Mindray Medical anticipates international business revenue of 17.65 billion yuan by 2025, accounting for 53% of total revenue [1] - Silis expects a record revenue of 165.05 billion yuan in 2025, with R&D investment increasing by 77.4% to 12.51 billion yuan [1] - Jixin Technology forecasts a net profit growth of 343.81% for 2025 [1] - Zhaoyan New Drug expects a net profit of 298 million yuan in 2025, a year-on-year increase of 302% [1] - Birun Technology anticipates a total revenue of 1.03 billion yuan in 2025, a 207% increase from the previous year [1] - Zhongji Xuchuang expects a net profit of 10.8 billion yuan in 2025, a year-on-year increase of 109%, and plans to distribute 10 yuan per 10 shares [1] - Salt Lake Co. anticipates a net profit growth of 81.76% in 2025, achieving revenue of 15.501 billion yuan [1] - CICC expects a net profit growth of 71.93% in 2025, planning to distribute 2.3 yuan per 10 shares [1] - Ninebot Company forecasts a net profit growth of 62.17% in 2025 [1] - Lianqi Technology expects a net profit growth of 58.4% in 2025 [1] - Zhaoyi Innovation anticipates a net profit growth of 49.47% in 2025, planning to distribute 7.5 yuan per 10 shares [1] - Zhongwei Company expects a net profit growth of 30.69% in 2025, planning to convert 10 shares into 4.9 shares and distribute 3.5 yuan [1] - Midea Group anticipates a net profit growth of 14.03% in 2025, planning to distribute 38 yuan per 10 shares and repurchase A-shares worth 6.5 billion to 13 billion yuan [1] - Ganfeng Lithium expects a net profit of 1.613 billion yuan in 2025, turning a profit from a loss [1] Quarterly Performance - Newray Co. expects a year-on-year net profit increase of 474%-604% in the first quarter, with price increases across the entire range of hard alloy and tool products [2] - Huarui Precision anticipates a year-on-year net profit increase of 413%-550% in the first quarter, driven by both volume and price increases [2]

Group 1 - The company has approved a plan to change its registered capital and amend its articles of association, increasing its total share capital from 667,277,972 shares to 701,102,451 shares [4][5] - The company completed the registration of additional shares from its stock option and restricted stock incentive plan, adding 571,379 shares [4] - The company issued 28,915,800 H-shares on January 13, 2026, and an additional 4,337,300 H-shares after exercising the over-allotment option [4] Group 2 - The company plans to use up to 1.3 billion RMB of idle raised funds to temporarily supplement its working capital, with a usage period of no more than 12 months [8][10] - As of December 31, 2025, the company had used a total of 2,232.18 million RMB of raised funds, with a remaining balance of 2,483.08 million RMB [9] - The company has established a mechanism for internal reporting and supervision of sustainable development, holding reports four times a year [3] Group 3 - The company reported a net profit of 1,648,022,651.70 RMB for the year 2025, with a proposed cash dividend of 0.75 RMB per share [52][53] - The total number of shares eligible for the dividend distribution is 700,499,431 shares, with a total cash dividend amounting to 525,374,573.25 RMB [53][54] - The company does not plan to convert capital reserves into share capital or issue bonus shares for the 2025 fiscal year [53]

Core Viewpoint - Xinhua Pharmaceutical is experiencing a situation of "increased revenue but decreased profit" for the second consecutive year, with significant declines in overseas revenue and a record low revenue growth rate over the past decade [1][3][4]. Financial Performance - In 2025, Xinhua Pharmaceutical achieved an operating revenue of 8.755 billion yuan, a year-on-year increase of 3.41%, while the net profit attributable to shareholders was 290 million yuan, down 38.32% year-on-year [2][3]. - The company's net profit excluding non-recurring items was 268 million yuan, a decrease of 40.10% year-on-year [1][2]. - The revenue growth rate of 3.41% in 2025 is the lowest in nearly 10 years, marking a trend of "increased revenue but decreased profit" for two consecutive years [3][4]. Revenue Breakdown - Domestic revenue in China reached 6.785 billion yuan, up 7.15% year-on-year, while revenue from the Americas fell by 19.09% to 746 million yuan, and revenue from Europe decreased by 10.72% to 713 million yuan [4]. Cost Management - Research and development expenses for 2024 and 2025 were 413 million yuan and 382 million yuan, respectively, showing a decline of 1.44% and 7.64% year-on-year [1][7]. - Sales expenses also decreased significantly, with 2025 sales expenses at 341 million yuan, down 41.67% year-on-year [5][9]. Product Development - In 2025, Xinhua Pharmaceutical obtained 47 drug approvals, a historical high, and launched 28 new formulations, with 27 more products accelerating towards market entry [6][8]. - The international formulation business saw a revenue increase of 19.86%, with self-operated formulation exports rising by 176.13% [6]. Strategic Outlook - The company remains optimistic about future growth opportunities, citing national strategic support for the pharmaceutical industry and the potential for domestic formulation exports [9].

Group 1 - Ganfeng Lithium (01772.HK) announced the resignation of Zhang Qichang as company secretary, authorized representative, and legal process document agent, effective from March 30, 2026 [1] - Liao Yilin and Wen Yongyi have been appointed as joint company secretaries, effective from March 30, 2026 [1] - Wen Yongyi has also been appointed as authorized representative and legal process document agent, effective from March 30, 2026 [1]

格隆汇3月31日丨赣锋锂业(01772.HK)发布公告，张启昌已辞任公司秘书、授权代表及法律程序文件代 理人，自2026年3月30日起生效。 廖轶琳及温咏宜已获委任为联席公司秘书，自2026年3月30日起生效。此外，温咏宜已获委任为授权代 表及法律程序文件代理人，自2026年3月30日起生效。 ...

Core Viewpoint - Ganfeng Lithium (01772.HK) announced the nomination of Liu Chongliang as an independent non-executive director candidate, pending approval by the shareholders' meeting [1] Group 1 - The board of Ganfeng Lithium has agreed to nominate Liu Chongliang for the position of independent non-executive director [1] - Liu's term will begin upon his election by the shareholders and will align with the term of the sixth board, excluding consecutive re-elections [1] - The appointment of Liu as an independent non-executive director is subject to approval at the company's shareholders' meeting [1]

格隆汇3月31日丨赣锋锂业(01772.HK)发布公告，董事会同意提名刘崇亮为独立非执行董事候选人。刘 先生的任期自其经股东会选举产生日起，与第六届董事会任期相同，连选连任除外。刘先生的委任为公 司独立非执行董事尚需提交公司股东会审议通过。 ...

Group 1 - The core viewpoint indicates that the spring sugar conference in 2026 will show clear signs of an industry bottom, with a noticeable decline in market enthusiasm [1] - Leading liquor companies are actively promoting lean operations and focusing on consumer-centered market development [1] - The current white liquor industry is in a deep adjustment phase, with pessimistic sentiments and expectations largely digested [1] Group 2 - It is believed that with improvements in the consumption environment, high-end liquor companies with solid consumer bases are likely to lead the sector's recovery [1] - The industry is at a cyclical bottom, and the cost-effectiveness of allocations is gradually becoming apparent, suggesting a strategy of increasing exposure to the white liquor sector during low points [1]

Group 1 - Ganfeng Lithium (01772) announced the resignation of Mr. Zhang Qichang as the company secretary, authorized representative, and legal process document agent [1] - Ms. Liao Yilin and Ms. Wen Yongyi have been appointed as co-company secretaries, with Ms. Wen also appointed as the authorized representative and legal process document agent [1] - These changes will take effect from March 30, 2026 [1]